157 results about "Mirna expression" patented technology

The present invention discloses a cancer-related genes finding method by using miRNA expression data, based on a pan-cancer program PanCancer under The Cancer Genome Atlas (TCGA), and uses statistical analysis and a machine learning algorithm to carry out analysis and processing on the gene expression data, and to identify complex diseases related genes. The method comprises: sorting out sample data; carrying out statistical analysis on the miRNA expression data; sorting miRNA in order of an average change rate; selecting a target gene; extracting a corresponding disease sample and normal sample; and using a Relief algorithm to sort genes in the extracted miRNA sample. The method disclosed by the present invention can find a plurality of risk genes related to cancer and other complex diseases, and has important significance to a biological target therapy, biomedical research, pathogenesis explanation, risk prediction, and the like.

The present invention provides a method for classification of thyroid tumors through the analysis of the expression patterns of specific microRNAs in fine needle aspiration samples. Thyroid tumor classification according to a microRNA expression signature allows optimization of diagnosis and treatment, as well as determination of signature-specific therapy.

The invention discloses a product for performing assisted prediction on postoperative survival time length of an esophageal squamous carcinoma patient. The product comprises substances for detecting 178 miRNA expression quantity substances comprising hsa-miR-218-5p, hsa-miR-142-3p, hsa-miR-150-5p and hsa-miR-205-5p, and records a carrier with the diagnostic criteria and functional expressions as follows: if 0.94dig is less than dip, the postoperative survival time of the esophageal squamous carcinoma patient to be tested is more than 5 years, and if the 0.94dig is more than or equal to dip, the postoperative survival time of the esophageal squamous carcinoma patient to be tested is less than 5 years. After the result of the postoperative survival time of the esophageal squamous carcinoma patient is predicted by using the product, more accurate and effective treatment is adopted, and the patient condition can be effectively improved. In addition, the medicine which influences the expression quantities of hsa-miR-218-5p, hsa-miR-142-3p, hsa-miR-150-5p and hsa-miR-205-5p can be used for treating the esophageal squamous carcinoma.

The invention relates to a miRNA function recognition method based on multi-genomics, and relates to a miRNA function recognition method based on multi-genome. The present invention aims to solve theproblem of low accuracy of miRNA function recognition in the prior art. The method of the invention comprises: analyzing differentially expressed genes through gene expression profiles; constructing disease-or drug-related protein networks; selecting functional modules of the constructed protein network related to disease or drug; performing enrichment analysis of the selected functional modules to determine the key genes in the functional modules; analyzing differentially expressed miRNAs by miRNA expression profiles to predict the target genes of differentially expressed miRNAs; performing construction of miRNA-regulated disease-or drug-related protein networks; performing functional enrichment analysis on the nodal genes of the constructed miRNA-regulated disease or drug-related proteinnetwork to identify the function of miRNA. The invention is used in the field of bioinformatics.

Methods and compositions are provided for diagnosing or detecting a condition, e.g., lung disease in a mammalian subject by use of a micro-RNA expression level or an expression level profile of multiple miRNA in the peripheral blood mononuclear cells (PBMC) of the subject which is characteristic of COPD or NSCLC. Detection of changes in expression in specific miRNA biomarkers from that of a reference sample or miRNA expression profile are correlated with non-small cell lung cancer (NSCLC) and/or COPD and permit differentiation among healthy subjects, subjects with COPD and subjects with adenocarcinoma or squamous cell carcinoma.

The invention provides a method for analyzing urine exosome miRNA, comprising: collecting a urine sample, extracting exosomes and their total RNA, establishing a cDNA library, performing Illumina sequencing, and processing and annotating the sequencing results to obtain expression information of sample miRNA expression quantity; urine sample exosome miRNA is analyzed by high-throughput sequencing technology to acquire expression information of miRNA; a database for IgA nephrotic patient and a healthy control patient is established, differentially expressed miRNA is deeply studied through target gene function prediction, the deep study on the differentially expressed miRNA helps further illustrate the pathogenesis of IgA nephropathy, and novel method and theoretical basis is provided for the diagnosis of IgA nephropathy. The method is reasonable and feasible in design, a noninvasive precise differential expression miRNA method can be effectively established, and novel ideas are provided for clinical diagnosis and treatment.

The invention relates a method for measuring miRNA absolute expression quantity in biological samples, which comprises the following steps: 1) material selection: 8 weeks and 40 weeks of mouse brain tissues are selected; 2) total RNA extract; 3) RT(reverse transcription)-Polymerase Chain Reaction (PCR); 4) quantifying DNA; 5) drawing specification curve; 6) data processing: loss rate and average loss rate of little RNA is figured out in the process of extracting RNA according to the copy number of spike RNA in the extracted total RNA which is detected by the PCR; the expression quantity of every initial cell of the little RNA at the levels of DNA and RNA is figured out according to the cell number of original sample that is respectively expressed from the levels of DNA and RNA. The method has the advantages of miRNA expression quantity is faithfully transformed into the absolute expression quantity in the original sample through the cell number in the sample homogenate which is worked out from the two levels of DNA and RNA; the disadvantage that relative differentiation can only be reflected by taking housekeeping genes as an internal reference, and the analysis is truer and more reliable from the two levels of DNA and RNA.

The invention discloses application of miR397 in the cultivation of drought-resistant plants, and by realizing the drought processing of paddy rice and detecting the miRNA expression level of processed samples, the invention discovers that the miR397 expression of the samples after the drought processing lies in a significant increasing trend, and the miR397 expression rise after the drought processing within 5 hours is more significant than the miR397 expression rise after the drought processing within 12 hours. The invention constructs a miR397 over-expression paddy rice mutant strain, which has better growth situation than wide paddy rice at relatively lower temperature and does not have obvious burliness difference with wide paddy rice, and results of simulated draught and post-draught recovery processing show that the paddy rice mutant strain has better drought resistance than wide paddy rice. The results provide a novel, simple and effective method for cultivating drought-resistant paddy rice and plants, which can be applied into large-scale popularization and application, does not cause environmental pollution and ensures food safety.

The invention discloses a method for in-situ joint detection of the expression of miRNA and fluorescence in-situ hybridization detection of apoptosis. The method comprises: synthesizing miRNA specific probe modified by LNA, labeling the probe with digoxin, purifying, biotinzing mouse anti-digoxin and constructing affinity-fluorescence labeling system and other basic steps. The invention can in-situ joint detect the expression of miRNA and apoptosis at the same time. The detection method of the invention converts the expression condition of miRNA to visible fluorescence signal, getting a good in-situ detection effect and filling a gap in the application of miRNA in-suit fluorescence detection.

The invention provides a miRNA-based disease relation analysis method and device. The method includes: constructing miRNA functional information according to miRNA expression of patients with a targetdisease and a normal control group; acquiring disease class information; calculating between-class distance between the miRNA functional information and the disease class information; constructing acomposite network according to the between-class distance, and generating disease relation information corresponding to the target disease. The method is detailed and accurate in analysis result and high in applicability, can be applied to molecular complex disease complication prediction analysis related theoretical researches and various clinical complex disease recovery assessment and has important significance to analysis in biology and medical science related fields.

The invention relates to methods for diagnosing Alzheimer's Disease (AD) with miRNA markers. Diagnosis of AD Towards the identification of biomarkers for diagnosis of AD, a comprehensive analysis of miRNA expression patterns was obtained. Significantly deregulated miRNAs were identified.

The invention relates to a serum micro ribonucleic acid (miRNA) biomarker used for detection of bladder cancer, overcomes the defects in the prior art, provides a miRNA marker circulating in serum of a patient having the bladder cancer, establishes a blood circulation miRNA expression profile of the patient having the bladder cancer, discloses the value of serum miRNAs in diagnosis of the bladder cancer, and provides support for early detection and early treatment of the patient having the bladder cancer clinically. According to the serum miRNA biomarker of the bladder cancer and a detection method of expression quantity of the serum miRNA biomarker, for the first time, the serum miRNAs, especially miR-663b and miR-497 can be used as an important indicator of biological detection and plays roles in clinical early diagnosis of the bladder cancer, differential diagnosis and effective observation, a theoretical basis is provided for research on the serum miRNAs of urinary system tumor in the future, novel ideas are provided for the diagnosis of the bladder cancer at the molecular level, and the serum miRNA biomarker of the bladder cancer and the detection method of expression quantity of the serum miRNA biomarker have great theoretical significance and potential practical value.

Disclosed are methods for detecting an allergic lung disease that involve assessing the level of one or more microRNAs (miRNAs) in a biological sample, wherein the level of the one or more miRNAs in the biological sample compared to a reference level of the one or more miRNAs is indicative of allergic lung disease. Also disclosed are methods for the treatment or prevention of inflammatory or allergic lung disease that involve administration of a let-7 miRNA inhibitor as set forth herein, as well as biochips and kits that can be applied in the methods of the present invention.

The present invention relates to vectors, compositions and methods for conditional, Cre-lox regulated, RNA interference. Vectors for use in conditional expression of a coding sequence based on a strategy in which the mouse U6 promoter is modified to include a hybrid between a LoxP site and a TATA box, and their use in conditional expression in transgenic mice are disclosed. The vectors allow for spatial and temporal control of miRNA expression in vivo.

This invention provides a method for displaying miRNA expression spectrum including: 1, processing a combined miRNA antisense oligonucleotide probe to a micro-array chip 2, oxidizing RNA molecular 3' end in the sample to a double-aldehyde group then to mark for the miRNA molecules by the hydrazide label molecules, 3, intercrossing the sample in step 1 and the micro-array chip in step 1 to test said mark. This invention also provides a reagent box for testing the miRNA.

The invention discloses a method for screening atherosclerosis related miRNA, which comprises the following steps: selecting ox-LDL (30mu g/ml) as a stimulating factor to stimulate human primary monocyte and induce the human primary monocyte to be differentiated into macrophage and foam cell, detecting the difference of cellular miRNAs expression in vitro by combining microarray analysis technology, screening the miRNAs which possibly participate in atherosclerosis reaction, and then using tagman probe fluorescent quantitative PCR verification and using a database and a computer software to analyze and forecast a possible target mRNA corresponding to the screened miRNAs; therefore, the method furthest screens the miRNA close to an atherosclerosis specific inflammation reaction pathological state, further completes a forming mechanism of atherosclerosis, and develops a new treatment target and a method for preventing and treating the atherosclerosis, in particular acute coronary events.

The invention designs an untranslated region specific artificial micro RNA (miRNA) capable of effectively inhibiting replication of porcine reproductive and respiratory syndrome (PRRS) virus strains, which belongs to the field of researches on gene engineering and biological products. The sequence of the miRNA is represented by one of SEQ ID No.1, SEQ ID No.2, SEQ ID No.3 and SEQ ID No.4. The invention also discloses the construction of an artificial miRNA expression vector based on RNA polymerase II, design of miRRNAi, synthesis and cloning of double-stranded oligo, detection of expression of miRNA and inhibition effect on replication of different PRRSV strains. Compared with siRNAs for genes of other PRRSVs, the artificial miRNA screened by the invention, according to the conservative sequence of the untranslated region, can inhibit the replication of homologous virus strains and heterologous virus strains and can be used in both the development of anti-PRRSV infection preparations and breeding transgenic pig disease resistance lines.

The invention relates to a non-small cell lung cancer detection primer and probe and kit. The kit comprises digital PCR master mix, a droplet stabilizer, miRNAs primer and probe mixed liquid and stem-loop reverse transcription primer mixed liquid, wherein the digital PCR master mix, the droplet stabilizer and the miRNAs primer and probe mixed liquid are used for preparing digital PCR reaction liquid; the stem-loop reverse transcription primer mixed liquid is used for carrying out RNA reverse transcription; the miRNAs primer and probe mixed liquid comprises forward primers and probes and a general reverse primer; the forward primers and probes are used for detecting hsa-mir-125b, hsa-mir-22, hsa-mir-128b and hsa-mir-16; the general reverse primer is used for detecting hsa-mir-125b, hsa-mir-22, hsa-mir-128b and hsa-mir-16; the stem-loop reverse transcription primer mixed liquid comprises stem-loop reverse transcription primers respectively used for reverse transcription of hsa-mir-125b, hsa-mir-22, hsa-mir-128b and hsa-mir-16; hsa-mir-125b, hsa-mir-22 and hsa-mir-128b are markers; hsa-mir-16 is internal reference. The non-small cell lung cancer detection kit can be used for rapidly, conveniently and accurately detecting the miRNA expression levels of non-small cell lung cancer patients.

The invention relates to a preparation method of establishing a reconstructed aviadenovirus for expressing infectious bursal disease virus (IBDV) miRNA, pertaining to the research field of gene engineering and biological product, comprising the selection of siRNA, the synthesis and cloning of double-stranded short-barrette oligonucleotide, the construction of virus transfer vector containing miRNA expression cassette aviadenovirus, the generation and identification of reconstructed virus expressed, the detection of the duplication function by miRNA to IBDV expressed by the reconstructed virus and the inhibition function to genetic expression. Compared with the prior art, the method can not only effectively and persistently express miRNA in bird cells, has specific and persistent inhibition to the duplication of virus and expression of gene of IBDV, but also has not infective function to poultry, which can be applied to in vitro experiments as well as be developed as a novel anti-avain-virus biological product.

The invention discloses a method of determining a tumor marker based on transcriptome data, comprising: (1) acquiring transcriptome data, including first and second transcriptome data which comprise mRNA, LncRNA and miRNA expression data of first and second individual sample respectively, wherein differences of the first and second individual samples include one of paired relative phenotypic features; (2) establishing regularization logic regression models wherein each individual has phenotypic feature relationship with expression of three RNAs, and using the models to regress expression data of the three RNAs respectively to obtain molecular regression coefficients of the three RNAs; (3) performing grid searching, and determining three RAN thresholds according to the molecular regression coefficients of the three RNAs; (4) comparing the molecular regression coefficient of each RNA to a corresponding threshold, and determining three RNA candidate markers; (5) mixing the three RNA candidate markers to obtain RAN mixture data, and replacing transcriptome data with the RAN mixture data to carry out the steps (2) to (4) so as to determine a tumor marker.

The invention relates to a miRNA expression model for diagnosing hepatic diseases independently. In the invention, an expression model of a miR-885-5p which is one of the circulating miRNAs associated with hepatic diseases is built by analyzing the types and relative expression levels of potential circulating miRNAs in a serum sample of a patient with cirrhosis or hepatocellular carcinoma and comparing the expression levels of the potential circulating miRNAs with the expression abundance of the circulating miRNAs in healthy reference serum. The model is formed by the expression indexes of the miR-885-5p, wherein the expression level of the miR-885-5p is higher than that of a healthy reference and is less tan 0.0001. ROC curve analysis shows that the hepatic disease HCC, LC and CHB identification efficacy AUC of the miR-885-5p and the healthy reference is 0.904, and the sensitivity and specificity of the miR-885-5p and the healthy reference are 90.5 percent and 79.2 percent respectively.